MY180772A - Novel therapeutic mirtazapine combinations for use in pain disorders - Google Patents

Novel therapeutic mirtazapine combinations for use in pain disorders

Info

Publication number
MY180772A
MY180772A MYPI2015703040A MYPI2015703040A MY180772A MY 180772 A MY180772 A MY 180772A MY PI2015703040 A MYPI2015703040 A MY PI2015703040A MY PI2015703040 A MYPI2015703040 A MY PI2015703040A MY 180772 A MY180772 A MY 180772A
Authority
MY
Malaysia
Prior art keywords
mirtazapine
combinations
novel therapeutic
pain disorders
inn
Prior art date
Application number
MYPI2015703040A
Inventor
Margarita Alekseevna Morozova
Allan Gerovich Beniashvili
Maksim Eduardovich Zapolsky
Original Assignee
Valenta Intellekt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valenta Intellekt Ltd filed Critical Valenta Intellekt Ltd
Publication of MY180772A publication Critical patent/MY180772A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to the field of medicine, and more particularly to psychopharmacology and psychoneurology. A combination of drugs comprising various active agents, which do not have a direct analgesic effect, in conjunction with one or more pharmaceutically acceptable vehicles, is provided for treating disorders associated with pain symptoms. The composition makes it possible to increase the effectiveness of treatment by virtue of the reduced dosage of drugs comprised in the composition, more particularly Mirtazapine (INN) and Tizanidine (INN), required for achieving the desired therapeutic effect.
MYPI2015703040A 2013-03-22 2014-03-17 Novel therapeutic mirtazapine combinations for use in pain disorders MY180772A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2013112747/15A RU2509560C1 (en) 2013-03-22 2013-03-22 New therapeutic combinations of mirtazapine applicable in pain conditions

Publications (1)

Publication Number Publication Date
MY180772A true MY180772A (en) 2020-12-09

Family

ID=50279596

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015703040A MY180772A (en) 2013-03-22 2014-03-17 Novel therapeutic mirtazapine combinations for use in pain disorders

Country Status (6)

Country Link
CN (1) CN105209044B (en)
EA (1) EA031906B1 (en)
MY (1) MY180772A (en)
RU (1) RU2509560C1 (en)
UA (1) UA112726C2 (en)
WO (1) WO2014148951A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ728036A (en) * 2014-01-21 2019-12-20 Wockhardt Ltd Pharmaceutical compositions comprising antibacterial agents
CN106243096B (en) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 The new application of tricyclic drugs
UA126916C2 (en) * 2017-04-27 2023-02-22 Др. Редді'З Лабораторіз Лімітед Pharmaceutical compositions of ketorolac
RU2736713C1 (en) * 2019-12-02 2020-11-19 Общество С Ограниченной Ответственностью "Валента - Интеллект" Combination of mirtazapine and tizanidine for use in pain disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL123716A (en) * 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent
WO2008009141A1 (en) * 2006-07-21 2008-01-24 Queen's University At Kingston Methods and therapies for potentiating a therapeutic action of an alpha- 2 adrenergic receptor agonist and inhibiting and/or reversing tolerance to alpha- 2 adrenergic receptor agonists

Also Published As

Publication number Publication date
WO2014148951A1 (en) 2014-09-25
EA201591603A1 (en) 2016-01-29
RU2509560C1 (en) 2014-03-20
CN105209044B (en) 2017-08-15
UA112726C2 (en) 2016-10-10
HK1214156A1 (en) 2016-07-22
CN105209044A (en) 2015-12-30
EA031906B1 (en) 2019-03-29

Similar Documents

Publication Publication Date Title
MX2022003072A (en) Use of pridopidine for treating functional decline.
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
MX2020004023A (en) Use of a pcsk9 inhibitor to treat hyperlipidemia.
IN2014DN10548A (en)
MX2017017138A (en) Targeted conjugates of ksp inhibitors.
MX2015012322A (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders.
MX2015001122A (en) Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor.
EA201590654A1 (en) COMBINATION OF RASAGILIN AND PRIDOPIDINE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS, IN PARTICULAR OF HANTINGTON'S DISEASE
MX2012014521A (en) Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation.
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX382776B (en) USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF TRAUMATIC INJURY.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2015005993A (en) Compositions and methods for the treatment of ectodermal dysplasia.
MX2015007280A (en) Combination therapy for cancer.
PH12015501538A1 (en) Topical ocular analgesic agents
GB201115977D0 (en) Neurodevelopmental disorders
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
MX2018015240A (en) Compositions comprising timolol and their use in the treatment of rosacea by topical administration.
NZ705229A (en) Pharmaceutical formulations containing ipidacrine and their use for the treatment of disorders of potency and disorders of other forms of sexual activity
BR112015002384A8 (en) pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and, optionally, a pi3k-alpha inhibitor, and their uses.
AR106220A1 (en) SPECIFIC HOMOGENIC SITE CONNECTORS WITH KSP INHIBITORS